Biomea Fusion, Inc. - Common Stock - Nakit Akışı (NASDAQ:BMEA)

Financials

İşletme faaliyetlerinden elde edilen nakit -35.44 M-62.42 M-96.59 M-119.89 M-70.37 M -56.37 M Yatırım faaliyetlerinden elde edilen nakit -33.35 M27.34 M-2.22 M-362 K-362 K — Finansman faaliyetlerinden elde edilen nakit 153.19 M1.24 M163.8 M1.67 M67.9 M — Serbest nakit akışı -35.44 M-62.42 M-96.59 M-119.89 M-70.37 M -56.37 M

Haberler

Citizens, diyabet tedavisi potansiyeli nedeniyle Biomea Fusion hissesi için kapsam başlattı

Biomea, tip 1 diyabet denemesinde olumlu sonuçlar açıkladı

Biomea Fusion, Inc. (BMEA) Discusses Menin Inhibition Mechanism and Therapeutic Potential in Diabetes Transcript

Biomea Fusion, Inc. (BMEA) Discusses Phase I Data and Clinical Potential of Oral GLP-1 Receptor Antagonist for Obesity Transcript

Biomea Fusion, Inc. (BMEA) Presents at 19th International Conference on Advanced Technologies & Treatments for Diabetes 2026 - Slideshow (NASDAQ:BMEA) 2026-03-16

Biomea Fusion, Inc. (BMEA) Presents at The Citizens Life Sciences Conference 2026 - Slideshow (NASDAQ:BMEA) 2026-03-12

Biomea Fusion, Inc. (BMEA) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow (NASDAQ:BMEA) 2026-01-16

Biomea Fusion, Inc. (BMEA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Rodman & Renshaw, Biomea Fusion hissesini Al tavsiyesi ile takibe aldı

Rodman & Renshaw initiates Biomea Fusion stock with Buy rating

Biomea Fusion, 2026 diyabet ve obezite ilaç geliştirme planlarını açıkladı

Biomea Fusion outlines 2026 diabetes and obesity drug development plans